Ibrahim Dagher

Ibrahim Dagher

No más puestos en curso

Fortuna: 84 683 $ al 31/08/2026

57 años
Health Technology
Consumer Services
Health Services

Perfil

Ibrahim B. Dagher worked as Senior Medical Director at Labcorp Drug Development, Inc. from 2018 to 2019.
From 2019 to 2021, served as Chief Medical Officer-WCG MedAvante-ProPhase at Cadent Therapeutics, Inc. Held the position of Chief Medical Officer at MedAvante-ProPhase, Inc. Worked as Chief Medical Officer at Enveric Biosciences, Inc. from 2021 to 2023.
From 2024 to 2026, held the role of Chief Medical Officer & Executive Vice President at Brainstorm Cell Therapeutics, Inc. Completed undergraduate education at Université de Bordeaux and Faculté De Médecine Necker Enfants Malades Université.

Participaciones conocidas en empresas públicas

EmpresaFechaNúmero de accionesValoraciónFecha de valoración
26/02/2026 79.515 ( 0,72 % ) 84 683 $ 31/08/2026

Antiguos cargos conocidos de Ibrahim Dagher.

EmpresasCargoFin
BRAINSTORM CELL THERAPEUTICS INC. Director Técnico/Científico/I+D 26/07/2026
ENVERIC BIOSCIENCES, INC. Director Técnico/Científico/I+D 01/01/2023
Corporate Officer/Principal 01/12/2021
COVANCE INC. Director Técnico/Científico/I+D 01/01/2019
Director Técnico/Científico/I+D -
Ver el detalle de la experiencia de Ibrahim Dagher.

Formación de Ibrahim Dagher.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Relaciones

30

Relaciones de 1er grado

7

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Empresas relacionadas

Empresas privadas7

Health Services

Health Technology

Consumer Services

Health Technology

Technology Services

Consumer Services

Health Technology

-40%: Ampliación de plazo extraordinaria
d
:
:
APROVECHAR LA PROMOCIÓN